#ASC48
Ascletis Pharma Unveils Groundbreaking Obesity Treatments at ObesityWeek® 2026#USA#Washington,_DC#Ascletis_Pharma#ASC37#ASC48
Ascletis Pharma Unveils Groundbreaking Obesity Treatments at ObesityWeek® 2026
Ascletis Pharma is set to showcase two innovative obesity treatments at ObesityWeek® 2026, highlighting their latest preclinical research.
third-news.com
November 2, 2026 at 8:59 AM
May 9, 2026 at 7:55 AM
Ascletis Develops a Revolutionary Fixed-Dose Combination for Obesity Treatment#China#Hong_Kong#Ascletis#ASC30#ASC48
Ascletis Develops a Revolutionary Fixed-Dose Combination for Obesity Treatment
Ascletis Pharma is advancing a pioneering oral treatment for obesity, featuring a unique combination of GIPR and GLP-1R agonists, set for FDA review.
third-news.com
July 15, 2026 at 10:09 AM